Featured Research

from universities, journals, and other organizations

Finasteride: Long-term survival of participants in prostate cancer prevention trial detailed

Date:
August 15, 2013
Source:
National Cancer Institute (NCI) at NIH
Summary:
Initial findings from a decade ago showed that the drug finasteride significantly reduced the risk of prostate cancer, but among those who did develop prostate cancer, paradoxically, the drug was associated with an increased risk of high-grade disease. Long term results show the small excess of higher grade tumors in the men in the finasteride arm of the study did not translate into an increased risk of death.

In the NCI-sponsored Prostate Cancer Prevention Trial (PCPT), initial findings from a decade ago showed that the drug finasteride significantly reduced the risk of prostate cancer, but among those who did develop prostate cancer, paradoxically, the drug was associated with an increased risk of high-grade disease.

New findings reported in NEJM on August 15, 2013, based on follow-up of trial participants for up to 18 years, showed that survival of the men on finasteride was equivalent to men who did not take the drug and the reduction in risk of prostate cancer persists.

Among nearly 19,000 eligible men who underwent randomization, prostate cancer was diagnosed in 10.5 percent of those in the finasteride group and 14.9 percent of those in the placebo group, a 30 percent reduction in risk. For the men diagnosed with prostate cancer, 10-year survival from time of diagnosis was equivalent between study groups overall (78 percent), in those with low-grade cancers (82 percent), and in those with high-grade cancers (73 percent) providing reassurance that the small excess of higher grade tumors in the men in the finasteride arm of the study did not translate into an increased risk of death.

Previous studies based on the original 2003 analysis had already suggested that the increase in high-grade disease may have been due to prostate gland shrinkage and increased sensitivity in detecting higher grade cancers. In fact, the PCPT was not designed specifically to address the question of high-grade disease.

Since 2011, drugs such as finasteride have had to carry a warning that they may increase the risk of high-grade prostate cancer; they have never been approved for the prevention of the disease. Specifically, there was concern that the increase in high-grade cancers detected among men receiving finasteride would result in more deaths. This new analysis was undertaken, in part, to understand if such concern was warranted.


Story Source:

The above story is based on materials provided by National Cancer Institute (NCI) at NIH. Note: Materials may be edited for content and length.


Journal Reference:

  1. Ian M. Thompson, Phyllis J. Goodman, Catherine M. Tangen, Howard L. Parnes, Lori M. Minasian, Paul A. Godley, M. Scott Lucia, Leslie G. Ford. Long-Term Survival of Participants in the Prostate Cancer Prevention Trial. New England Journal of Medicine, 2013; 369 (7): 603 DOI: 10.1056/NEJMoa1215932

Cite This Page:

National Cancer Institute (NCI) at NIH. "Finasteride: Long-term survival of participants in prostate cancer prevention trial detailed." ScienceDaily. ScienceDaily, 15 August 2013. <www.sciencedaily.com/releases/2013/08/130815161443.htm>.
National Cancer Institute (NCI) at NIH. (2013, August 15). Finasteride: Long-term survival of participants in prostate cancer prevention trial detailed. ScienceDaily. Retrieved July 31, 2014 from www.sciencedaily.com/releases/2013/08/130815161443.htm
National Cancer Institute (NCI) at NIH. "Finasteride: Long-term survival of participants in prostate cancer prevention trial detailed." ScienceDaily. www.sciencedaily.com/releases/2013/08/130815161443.htm (accessed July 31, 2014).

Share This




More Health & Medicine News

Thursday, July 31, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
At Least 20 Chikungunya Cases in New Jersey

At Least 20 Chikungunya Cases in New Jersey

AP (July 30, 2014) At least 20 New Jersey residents have tested positive for chikungunya, a mosquito-borne virus that has spread through the Caribbean. (July 30) Video provided by AP
Powered by NewsLook.com
Xtreme Eating: Your Daily Caloric Intake All On One Plate

Xtreme Eating: Your Daily Caloric Intake All On One Plate

Newsy (July 30, 2014) The Center for Science in the Public Interest released its 2014 list of single meals with whopping calorie counts. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

    Environment News

    Technology News



      Save/Print:
      Share:

      Free Subscriptions


      Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

      Get Social & Mobile


      Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

      Have Feedback?


      Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
      Mobile: iPhone Android Web
      Follow: Facebook Twitter Google+
      Subscribe: RSS Feeds Email Newsletters
      Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins